Andere Sprachen Oncolytics Biotech Inc.

Aktien

A2JMW5

CA6823108759

ONC

Markt geschlossen - Toronto S.E. Andere Börsenplätze 21:59:59 25.06.2024			% 5 Tage	% 1. Jan.
1,37 ^CAD	0,00 %		-1,44 %	-23,46 %

24.06.	Oncolytics Biotech CEO Matt Coffey lässt sich aus medizinischen Gründen beurlauben	MT
24.05.	Oncolytics Biotech Inc. präsentiert zwei Abstracts auf der Jahrestagung 2024 der American Society of Clinical Oncology	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Oncolytics Biotech CEO Matt Coffey to Take Medical Leave of Absence	24.06.
Oncolytics Biotech President and CEO Coffey to Take Medical Leave of Absence	24.06.
Oncolytics Biotech Brief: Announcing President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence	24.06.
Oncolytics Biotech Doses First Patient in Pelareorep Study Involving Modified FOLFIRINOX	20.06.
Oncolytics Biotech Brief: Says Dosed First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer	20.06.
Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer	20.06.
Oncolytics Biotech Inc. Presents Two Abstracts At the 2024 American Society of Clinical Oncology Annual Meeting	24.05.
Oncolytics Biotech Says ASCO Abstracts Highlight Pelareorep's Treatment Potential in Pancreatic Cancer	24.05.
Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action	24.05.
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders	16.05.
Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Pancreatic Cancer Trial	15.05.
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial	15.05.
Oncolytics Biotech Brief: Announcing Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial	15.05.
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial	15.05.
Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial	15.05.
RBC on Oncolytics Biotech's Upcoming Type C Meeting With FDA	13.05.
Oncolytics Biotech Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer	10.05.
Oncolytics Biotech Reports a First-Quarter Loss of Near $7 Million	09.05.
Oncolytics Biotech Brief: Q1 Basic and diluted loss per common share $0.09	09.05.
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights	09.05.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Oncolytics Biotech Inc.

Aktien

A2JMW5

CA6823108759

ONC

Andere Sprachen

Filter